Summary
AbbVie Inc. (ABBV) filed an 8-K on November 2, 2018, primarily to report its third-quarter financial results for the period ended September 30, 2018. The press release announcing these results, furnished as Exhibit 99.1, contains the core financial and operational details investors would need to assess the company's performance during the quarter. This filing serves as the official record of AbbVie's Q3 2018 financial disclosures.
Key Highlights
- 1AbbVie announced its third-quarter 2018 financial results on November 2, 2018.
- 2The 8-K filing contains a press release detailing the Q3 2018 financial performance.
- 3This report is primarily an informational filing to disseminate earnings information.
- 4Investors can refer to Exhibit 99.1 for the full press release and detailed financial data.
- 5No other material events or business changes were disclosed in this specific 8-K filing, beyond the Q3 earnings.
Frequently Asked Questions
The main purpose of this 8-K filing from AbbVie Inc., dated November 2, 2018, is to officially report and disseminate its financial results for the third quarter ended September 30, 2018. This is done by furnishing a press release containing these results.
The specific financial details for AbbVie's third quarter ended September 30, 2018, are located within the press release furnished as Exhibit 99.1 to this 8-K filing.
Based on the provided filing information, this 8-K is solely focused on the announcement of third-quarter financial results. It does not appear to disclose any other significant new business developments or corporate changes at this time.